Skip to main content
. 2015 Dec 16;15:949. doi: 10.1186/s12885-015-1978-2

Fig. 6.

Fig. 6

Comparison of non-hematological adverse events between irinotecan-based chemotherapy and non-irinotecan-based chemotherapy as first-line treatment in patients with stage IIIB/IV NSCLC